Intravenous bisphosphonates in the prevention of osteoporosis associated with stroke

Cambridge University Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 30 人开始时间: 2005年8月23日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•For inclusion, males and females aged 40-89 will be approached as soon as possible after admission with first ever stroke. Patients will be eligible if they were previously independently walking, have clinical and computed tomography (CT) evidence of stroke (haemorrhagic or ischaemic), are unable to walk 1 week following stroke (Functional Ambulatory Category [FAC] 0 or 1) and can give written informed consent to the study.

•Exclusion criteria are as follows:
•A. Not walking independently prior to stroke/previous stroke causing hemiplegia
•B. Stroke not affecting the lower limb/FAC >1 at 1 week post stroke/posterior circulation stroke
•C. Unconsciousness or terminal illness
•D. Pre-existing dementia or cognitive impariment
•E. Aphasia/significant language impairment
•F. Renal/hepatic impairment
•G. Aged <40 and >89
•H. Prior treatment with a bisphosphonate, corticosteroids/known osteoporosis/unilateral bone disease affecting BMD/prior hip fracture or osteosynthetic material at the hip (e.g. hip replacement)
•I. Unable to randomise and give infusion within 35 days of stroke (e.g. tertiary referrals from another hospital)
•J. Current treatment with an aminoglycoside antibiotic

发起方